Pharmacogenomic tests of oncology drugs at Instituto Nacional de Câncer (INCA)
The implementation, current status and future perspectives of the pharmacogenetics/genomics (PGx) testing program developed at Instituto Nacional de Cancer (INCA) are presented. Initial selection of drug-gene pairs for PGx testing was based on clinically-validated PGx associations and availability o...
Saved in:
| Main Author: | Guilherme Suarez-Kurtz |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Revinter Publicações Ltda.
2021-10-01
|
| Series: | Brazilian Journal of Oncology |
| Subjects: | |
| Online Access: | http://www.brazilianjournalofoncology.com.br/details/152/en-US/pharmacogenomic-tests-of-oncology-drugs-at-instituto-nacional-de-cancer--inca- |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacogenomic tests in Oncology - finding the right dose
by: Jeziel Basso, et al.
Published: (2021-10-01) -
Thiopurine S-methyl Transferase (TPMT) Enzyme Level in Healthy Sudanese Population
by: Rayan Khalid, et al.
Published: (2024-09-01) -
Study of polymorphisms of UGT1A1 and DPYD genes in chemotherapy for colorectal cancer
by: N. N. Timoshkina, et al.
Published: (2019-01-01) -
Balance of care activity after EMA recommendation for DPYD gene testing in Galicia
by: Almudena Gil-Rodríguez, et al.
Published: (2025-03-01) -
Dose-Limiting Toxicities and the Maximum Tolerated Dose of Irinotecan Based on <i>UGT1A1</i> Genotypes: A Systematic Review
by: Xando Díaz-Villamarín, et al.
Published: (2025-04-01)